Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s662, 2025. DOI: 10.25251/t6v95c18. Disponível em: https://skin.dermsquared.com/skin/article/view/3848. Acesso em: 29 apr. 2026.